SEC Comment Letter 0000000000-23-003240 to Jounce Therapeutics, Inc. (CIK 0001640455)
Jounce Therapeutics, Inc. (CIK 0001640455)
Date: March 30, 2023 · CIK: 0001640455 · Accession: 0000000000-23-003240
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo March 30, 2023 Jacquelyn Fahey Sandell Chief Legal Officer Jounce Therapeutics, Inc. 780 Memorial Drive Cambridge, Massachusetts 02139 Re:Jounce Therapeutics, Inc. Schedule 14D-9 filed March 27, 2023 File No. 005-89831 Dear Jacquelyn Fahey Sandell: We have reviewed your filing and have the following comment. Please respond to this comment by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to these comments, we may have additional comments. Schedule 14D-9 filed March 27, 2023 Additional Information and Where to Find It 1.The SEC Reference Room no longer provides a means for shareholders to access periodic report filings; however, those filings are generally available on the SEC's EDGAR system. Please revise your disclosure accordingly. General 2.This filing incorrectly uses the EDGAR "tag" for a Schedule 14D-9, when it should be filed as a Schedule 14D-9C. All future preliminary communication filings should be made under cover of Schedule 14D-9C. Please confirm your understanding in your response letter. We remind you that the filing persons are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameJacquelyn Fahey Sandell Comapany NameJounce Therapeutics, Inc. March 30, 2023 Page 2 FirstName LastName Jacquelyn Fahey Sandell Jounce Therapeutics, Inc. March 30, 2023 Page 2
Please direct any questions to Christina Chalk at 202-551-3263 or Blake Grady at 202- 551-8573. Sincerely, Division of Corporation Finance Office of Mergers & Acquisitions
Show Raw Text
United States securities and exchange commission logo
March 30, 2023
Jacquelyn Fahey Sandell
Chief Legal Officer
Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge, Massachusetts 02139
Re:Jounce Therapeutics, Inc.
Schedule 14D-9 filed March 27, 2023
File No. 005-89831
Dear Jacquelyn Fahey Sandell:
We have reviewed your filing and have the following comment.
Please respond to this comment by providing the requested information or advise us as
soon as possible when you will respond. If you do not believe our comment applies to your facts
and circumstances, please tell us why in your response.
After reviewing your response to these comments, we may have additional comments.
Schedule 14D-9 filed March 27, 2023
Additional Information and Where to Find It
1.The SEC Reference Room no longer provides a means for shareholders to access periodic
report filings; however, those filings are generally available on the SEC's EDGAR system.
Please revise your disclosure accordingly.
General
2.This filing incorrectly uses the EDGAR "tag" for a Schedule 14D-9, when it should be
filed as a Schedule 14D-9C. All future preliminary communication filings should be
made under cover of Schedule 14D-9C. Please confirm your understanding in your
response letter.
We remind you that the filing persons are responsible for the accuracy and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameJacquelyn Fahey Sandell
Comapany NameJounce Therapeutics, Inc.
March 30, 2023 Page 2
FirstName LastName
Jacquelyn Fahey Sandell
Jounce Therapeutics, Inc.
March 30, 2023
Page 2
Please direct any questions to Christina Chalk at 202-551-3263 or Blake Grady at 202-
551-8573.
Sincerely,
Division of Corporation Finance
Office of Mergers & Acquisitions